Global biopharmaceutical company Antengene and AI-powered drug R&D company XtalPi announced a long-term R&D collaboration with the mission to revolutionise drug discovery and development by improving the speed, scale, novelty and success rate.
Under the terms of the agreement, XtalPi will utilize its integrated artificial intelligence (AI) research and development (R&D) platform consisting of proprietary cloud-supercomputer-powered in silico tools and its highly efficient wet lab to support Antengene’s drug discovery and development programs.
Also Read: Are Businesses Meeting A Net-Zero Carbon Future?
“This collaboration is in keeping with Antengene’s mission of bringing best-in-class/first-in-class medicines for people with cancer and other life-threatening diseases. We are very excited about the opportunity to accelerate the pace of candidate identification, selection and preclinical evaluation by working with XtalPi to conduct in silico compound synthesis and testing. We believe this technology will allow us to explore a wider chemical space which could be especially valuable for completely new targets” said Dr Jay Mei, Founder and CEO of Antengene.
Dr. Ma Jian, CEO of XtalPi said “The excellent cooperation and potential for a long-term collaboration between XtalPi and Antengene is based on the good trust established by both parties. I believe that XtalPi’s pioneering, AI-driven technology can help our partner, Antengene, develop new therapies at a pace and scale beyond traditional alternatives. The positive scientific collaboration between the scientists at XtalPi and Antengene sets the stage for a ‘win-win relationship’ that can provide a mutual benefit to both parties.”
Under the terms of the agreement, XtalPi will utilise its integrated artificial intelligence (AI) research and development (R&D) platform comprised of proprietary cloud-supercomputer-powered in silico tools and its highly efficient wet lab to support Antengene’s drug discovery and development programs.
